Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 5879

Similar articles for PubMed (Select 16168838)

1.
3.

Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.

Ishiyama H, Kitano M, Satoh T, Kotani S, Uemae M, Matsumoto K, Okusa H, Tabata K, Baba S, Hayakawa K.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):23-8. doi: 10.1016/j.ijrobp.2008.11.006. Epub 2009 Feb 23.

PMID:
19243900
5.

Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.

Pellizzon AC, Nadalin W, Salvajoli JV, Fogaroli RC, Novaes PE, Maia MA, Ferrigno R.

Radiother Oncol. 2003 Feb;66(2):167-72.

PMID:
12648788
7.

Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.

Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, Gustafson G, Ye H, Martinez A.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):204-12. doi: 10.1016/j.ijrobp.2010.10.009. Epub 2010 Dec 16.

PMID:
21167653
8.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
9.

A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.

Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A.

J Urol. 2005 Sep;174(3):882-7.

PMID:
16093980
10.

High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.

Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS.

J Urol. 2004 Mar;171(3):1098-104.

PMID:
14767279
11.

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.

Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.

Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52.

PMID:
10802358
12.

Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.

Pinkawa M, Fischedick K, Treusacher P, Asadpour B, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ.

Radiother Oncol. 2006 Jan;78(1):41-6. Epub 2005 Nov 4.

PMID:
16271785
13.

High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer.

Chin YS, Bullard J, Bryant L, Bownes P, Ostler P, Hoskin PJ.

Clin Oncol (R Coll Radiol). 2006 Aug;18(6):474-9.

PMID:
16909971
14.

High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity.

Yoshioka Y, Nose T, Yoshida K, Oh RJ, Yamada Y, Tanaka E, Yamazaki H, Inoue T, Inoue T.

Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):213-20.

PMID:
12694841
15.

Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.

Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S.

Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):59-67.

PMID:
10477007
16.

High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.

Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS.

Am J Clin Oncol. 2010 Oct;33(5):481-8. doi: 10.1097/COC.0b013e3181b9cd2f.

PMID:
19952715
17.

Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.

Fang FM, Wang YM, Wang CJ, Huang HY, Chiang PH.

Jpn J Clin Oncol. 2008 Jul;38(7):474-9. doi: 10.1093/jjco/hyn056. Epub 2008 Jul 11.

18.

Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.

Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M 3rd, Sandler HM, Markoe AM, Cox JD.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):735-42.

PMID:
14967428
19.

Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate.

Okamoto M, Ishikawa H, Ebara T, Kato H, Tamaki T, Akimoto T, Ito K, Miyakubo M, Yamamoto T, Suzuki K, Takahashi T, Nakano T.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e211-7. doi: 10.1016/j.ijrobp.2011.03.041. Epub 2011 May 27.

PMID:
21620579
20.

Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.

Ares C, Popowski Y, Pampallona S, Nouet P, Dipasquale G, Bieri S, Ozsoy O, Rouzaud M, Khan H, Miralbell R.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):656-63. doi: 10.1016/j.ijrobp.2008.11.023. Epub 2009 Feb 26.

PMID:
19250768
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk